Witte Jan De (Director) sold ~$102K of ResMed|
Planned saleWant the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
RMD · NYSE · Health Care Equipment
ResMed| (RMD) · oqro.io/stocks/RMD · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of ResMed| was filed in the last 90 days. The latest on record was on Aug 17, 2016.
Since 2006, ResMed| insiders reported 2 open-market purchases and 1,071 sales on Forms 4 and 5, with purchases in 2 different years, most recently 2016.
In the last 90 days, 3 insiders of ResMed| (RMD) reported 5 open-market sales worth $3.74M in total on SEC Form 4. The largest seller by value was Michael J. Farrell, with $3.41M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Yes. Members of Congress disclosed 1 trade in ResMed| (RMD) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent is from Sen. Alan Armstrong.
ResMed|'s next results are expected on Jan 27, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$236.88−5.73 (−2.36%)
Close of Nov 19, 2026, vs Nov 18 · end-of-day, not a live quote
−3.3% (−$8.11) from Nov 19, 2025 to Nov 19, 2026 · adjusted daily closes
Adjusted close went from $244.99 on Nov 19, 2025 to $236.88 on Nov 19, 2026 (−3.3%). Disclosed in this range: 0 insider trades, 30 pre-arranged insider sales, 1 Congress trade, and 50 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Equipment company based in San Diego, California.
Last 12 months
−3.3%
Market value
$33.5B
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 10.5M shares sold short (7.4% of shares outstanding), −12.2% vs the previous count, 7.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$1.41B
+5.9% vs the same quarter a year earlier
Free cash flow, last 12 months
$1.61B
This quarter $374M, a year earlier $414M
Net cash
$761M
Debt $250M, cash $1.01B, at Sep 30, 2026
Backlog
$386M
Work contracted but not yet delivered, as the company reports it
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 29, 2026.
Revenue, fiscal 2026
$5.65B
+9.9% vs the year before
Net income, fiscal 2026
$1.52B
As reported in the annual filing
Shares outstanding
141M
As of Oct 26, 2026
In fiscal 2026 the company spent $700M buying back its own shares and $350M on dividends. Cash actually paid, from its cash-flow statement.
Last dividend: $0.66 a share (quarterly), ex-date Nov 12, 2026, payable Dec 17, 2026. Calendar
Witte Jan De (Director) sold ~$102K of ResMed|
Planned saleDe Witte Jan (Director) plans to sell ~$102K of ResMed|
Planned, from payFund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Michael J. Farrell (Officer) plans to sell ~$1.18M of ResMed|
Planned, from payPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
On the public record for ResMed| over the 12 months to Nov 19, 2026: 7 FDA records and 1 executive contribution.
Insiders of ResMed| reported 2 open-market purchases and 1,071 sales since 2006; purchases in 2 different years, most recently 2016.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $17.6M24×24 trades |
| 2025 | — | $38.5M50×50 trades |
| 2024 | — | $48.7M34×34 trades |
| 2023 | — | $28.3M43×43 trades |
| 2022 | — | $45.7M43×43 trades |
| 2021 | — | $45.3M61×61 trades |
| 2020 | — | $31.8M65×65 trades |
| 2019 | — | $46.3M97×97 trades |
| 2018 | — | $18.7M52×52 trades |
| 2017 | — | $46.9M54×54 trades |
| 2016 | $172K1×1 trade | $50.1M57×57 trades |
| 2015 | — | $52.6M84×84 trades |
| 2014 | — | $41.5M73×73 trades |
| 2013 | — | $51.3M57×57 trades |
| 2012 | — | $32.9M32×32 trades |
| 2011 | — | $20.9M29×29 trades |
| 2010 | — | $57.4M67×67 trades |
| 2009 | — | $25.6M59×59 trades |
| 2008 | — | $6.68M24×24 trades |
| 2007 | — | $16.3M41×41 trades |
| 2006 | $425K1×1 trade | $18.5M25×25 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Top officer leaving
“(the “Company”) announced that Brett Sandercock, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, will retire from his role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer.”
3 insiders sold ~$3.83M in the 60 days before
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
7 certified in FY2026 Q3, vs 10 a year earlier. 7 positions in total, median offered wage $157K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Last results
Oct 29, 2026
Within the 30 days after it, until Nov 28, 2026
Next results, expected
Jan 27, 2027
Purchases after results
Not enough history
From ResMed|'s own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know ResMed|'s policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Congress
Funds and stakes
Contracts, lobbying and filings
People read ResMed|'s Wikipedia article about 58 times a day over the last week, close to the 68 on a usual day of the three months before.
6 approvals or clearances and 1 recall recorded by the FDA for this company and its listed subsidiaries.
Company reports, price and press
Who holds it
Deals
Attention
Things to keep in mind
Records
May 14, 2026Busiest day: 210 views on Jul 15, 2026Nov 18, 2026
Views of the article ResMed, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Fiscal year Jul 1, 2025 to Jun 30, 2026, from the annual report filed Aug 13, 2026. Read the filing
+10% on the year before ($4.5B). Operating income $2.2B, a 44% margin
+5.4% on the year before ($641M). Operating income $218M, a 32% margin
+10% on the year before ($4.5B)
+5.4% on the year before ($641M)
+8.4% on the year before ($3.29B)
+12% on the year before ($1.86B)
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 8,000 words.
We are a global leader in digital health and cloud-connected medical devices. We design innovative technology with the intention to empower people to live happier, healthier lives. Our artificial intelligence, or AI, powered digital health solutions, cloud-connected devices and intelligent software are designed to make home healthcare more personalized, accessible and effective. By enabling better care, our products seek to improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems.
Source: SEC EDGAR, Form 10-K filed Aug 13, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Latest annual report filed Aug 13, 2026, compared with the one filed Aug 8, 2025. Read the filing
We are involved in various legal proceedings, claims, investigations and litigation that arise in the ordinary course of our business. See Note 15 – Legal Actions, Contingencies and Commitments of the Notes to Consolidated Financial Statements (Part II, Item 8) included in this report, which is incorporated by reference herein. Litigation is inherently uncertain. Accordingly, we cannot predict with certainty the outcome of these matters. But we do not expect the outcome of these matters to have a material adverse effect on our consolidated financial statements when taken as a whole.
And 10 more headings in the filing.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Aug 13, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Vanguard Capital Management
13G · passive · Crossed 5% · 12M shares · filed Apr 29, 2026
AustralianSuper Pty Ltd
13G · passive · Crossed 5% · 8.28M shares · filed Aug 7, 2026
Vanguard Portfolio Management
13G · passive · Crossed 5% · 7.89M shares · filed Apr 29, 2026
Recent moves
AustralianSuper Pty Ltd went above 5%, with 5.7% · Schedule 13G, 2026
Vanguard Portfolio Management went above 5%, with 5.41% · Schedule 13G, 2026
Vanguard Capital Management went above 5%, with 8.21% · Schedule 13G, 2026
The Vanguard Group fell below 5% (0%) · Schedule 13G, 2026
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Against the S&P 500 over the year
Since Nov 18, 2025, RMD is down 3.8% and the index fund is up 8.5%: 12 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much RMD moves
Beta 0.5 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Short sale volume: 69.7% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 72.6%. FINRA daily files, to Nov 19, 2026.
Fails to deliver: 13K shares (about $3.36M) were not delivered on time for settlement on Oct 28, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 45.1% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (31.2% on ATS, 13.9% with other brokers), close to its 26-week average of 43.7%. Weeks of Oct 5 to Oct 30, 2026.
Largest ATS: SIGMA X2 (13.4%), INTELLIGENT CROSS LLC (13.4%), UBS ATS (11.8%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.